FDA says yes, Wall Street says “meh”
Spectral AI (MDAI) just picked up a meaningful regulatory win: the FDA granted De Novo Classification for its DeepView System, a tool used in burn care across different settings. That’s the kind of milestone companies spend years chasing, because it can open the door to broader commercial use and make the product look a lot less like a science fair project and a lot more like a real business.
So why is the stock down?
Because the market is a beautifully irrational place. Shares were off about 12% in Tuesday morning trading even after the green light, which tells you investors may have been expecting this win, or are already moving on to the next question: can Spectral AI actually turn regulatory victory into revenue?
The big investor question
For a company like this, FDA clearance is the opening bell, not the finish line. What matters next is whether DeepView can get traction in hospitals and burn centers, convert attention into orders, and prove it can scale without turning cash burn into a bonfire.
Big picture: regulatory approval is great, but in small-cap medtech, the market usually wants the sequel — sales, adoption, and a path to not living on hope alone.